IMC-3C5

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMC-3C5, covering 2019-06-17 to 2019-06-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors [Phase 1]